CryoLife

Artivion, Inc. focuses on developing solutions that address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment provides cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

The stock price of Cryolife Inc (NYSE: CRY) increased from $23.49 to over $27 during intraday trading this morning. This is why it happened.

CRY Stock: From $23.49 To Over $27 Explanation

CryoLife (CRY) delivered earnings and revenue surprises of 27.27% and 15.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Reports Q1 Loss, Tops Revenue Estimates

Shares of Cryolife (NYSE:CRY) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 137.50% year over year to $0.03, which beat the estimate of ($0.09).

Cryolife: Q1 Earnings Insights

ATLANTA, April 29, 2021 /PRNewswire/ -- First Quarter and Recent Business Highlights: Achieved total revenues of $71.1 million in the first quarter 2021 versus $66.4 million in the first quarter of 2020, an increase of 7% on a GAAP basis and 3% on a non-GAAP proforma constant currency basis Net loss was ($3.1) million, or ($0.08) per share, in the first quarter of 2021 Non-GAAP net income was $1.4 million, or $0.03 per share, in the first quarter of 2021 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the first quarter ended March 31, 2021.  "Despite the ongoing impact of COVID-19 on our business, we saw our business return to growth on both a GAAP and proforma constant currency basis in the first quarter.

CryoLife Reports First Quarter 2021 Financial Results

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CryoLife (CRY) Q1 Earnings Expected to Decline

ATLANTA, April 15, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2021 financial results will be released on Thursday, April 29, 2021 after the market closes.  On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2021 Financial Results

ATLANTA, April 7, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021.  The Company's virtual fireside chat is scheduled to begin at 8:45 a.m.

CryoLife to Participate in 20th Annual Needham Virtual Healthcare Conference

ATLANTA, March 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Oppenheimer 31st Annual Virtual Healthcare conference on Tuesday, March 16 - 17, 2021.  The Company's virtual fireside chat is scheduled to begin at 11:20 a.m.

CryoLife to Participate in Oppenheimer 31st Annual Virtual Healthcare Conference

CryoLife's (CRY) CEO Pat Mackin on Q4 2020 Results - Earnings Call Transcript

CryoLife (CRY) delivered earnings and revenue surprises of 1100.00% and 4.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Beats Q4 Earnings and Revenue Estimates

Shares of Cryolife (NYSE:CRY) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 81.82% over the past year to $0.20, which beat the estimate of $0.03.

Recap: Cryolife Q4 Earnings

CryoLife has a resilient portfolio mix that is bolstered by upcoming regulatory catalysts. The company has decent upside potential through operations, however, this may already be reflected in valuations.

CryoLife: Upside Potential Via Operating Leverage But Liquidity Pressures Loom

ATLANTA, Nov. 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company's ongoing PROACT Xa trial on December 7,...

CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020

CryoLife's (CRY) CEO Pat Mackin on Q3 2020 Results - Earnings Call Transcript

CryoLife (CRY) delivered earnings and revenue surprises of 1400.00% and 12.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Q3 Earnings and Revenues Surpass Estimates

ATLANTA, Oct. 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes. On that day, the...

CryoLife Announces Release Date and Teleconference Call Details for 2020 Third Quarter Financial Results

ATLANTA, Sept. 8, 2020 /PRNewswire/ -- CryoLife, Inc.

CryoLife to Present at the 18th Annual Morgan Stanley Global Healthcare Conference

ATLANTA, Sept. 2, 2020 /PRNewswire/ -- CryoLife, Inc.

CryoLife Acquires Ascyrus Medical

CryoLife's (CRY) CEO Pat Mackin on Q2 2020 Results - Earnings Call Transcript

ATLANTA, July 30, 2020 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second quarter of 2019 - Total revenues decreased 24% and decreased 23% on a non-GAAP constant currency.

CryoLife Reports Second Quarter 2020 Financial Results

Analysts Estimate CryoLife (CRY) to Report a Decline in Earnings: What to Look Out for

ATLANTA, July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial results will be released on Thursday, July 30, 2020 after the market closes.

CryoLife Announces Release Date and Teleconference Call Details for 2020 Second Quarter Financial Results

ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025...

CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering

CryoLife Inc. CRY, -0.72% said Thursday it is planning to offer $100 million in convertible senior notes that mature in 2024 in a private placement, joining the many companies issuing debt to bolster liquidity during the coronavirus pandemic.

CryoLife to offer $100 million of 5-year convertible notes

ATLANTA, June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate...

News for CryoLife Stock (CRY)